Infinity (INFI) Incurs In-Line Loss In Q1, Maintains View
Zacks Investment Research | May 09, 2018 02:12AM ET
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) reported a loss of 18 cents per share in first-quarter 2018, in line with the Zacks Consensus Estimate. The company had reported a loss of 21 cents in the year-ago quarter.
Since Infinity does not have any approved product in its portfolio, the company earns revenues in the form of royalties, license and milestone payments as well as research and development (R&D) support fees paid by its partners.
Infinity’s shares have returned 2.5% year to date against the industry ’s decline of 2.9%.
Quarter in Detail
In the quarter, R&D expenses increased 38.8% to $5.9 million due to higher clinical development charges for IPI-549.
General and administrative (G&A) expenses were $3.6 million for the quarter, down 43.8% from the year-ago quarter. The decrease was mainly due to a reduction in bonus and stock compensation.
2018 Outlook
Infinity reaffirmed its outlook for 2018. The company expects net loss for 2018 to be in the range of $35-$45 million. The company anticipates year-end cash and cash equivalents and available-for-sale securities balance in the $15-$25 million range. Moreover, Infinity expects that its existing cash, cash equivalents and available-for-sale securities as of Dec 31, 2017 should be adequate to fund the company's capital needs through third-quarter 2019.
Other Updates
Infinity is evaluating IPI-549 as a monotherapy and in combination with Bristol-Myers’ (NYSE:BMY) Opdivo in a phase I study in patients with advanced solid tumors.
The phase I/Ib monotherapy and combination dose escalation components of the study have been completed. Enrollment, which began in 2018, is ongoing for six disease-specific combination expansion cohorts, along with a seventh combination expansion cohort of patients pre-selected for having high baseline blood levels of myeloid derived suppressor cells (MDSCs).
The company expects to report data from the monotherapy expansion component and combination dose-escalation component of the study in 2018. The company also expects to report initial data from six disease-specific combination expansion cohorts in 2018.
Further, the company expects to report more mature clinical and translational data (including insights from paired tumor biopsies) from the six disease-specific cohorts and initial data from the cohort of patients pre-selected for having high baseline blood levels of MDSC in the combination expansion component of the study in the second half of 2018.
Get The News You Want
Zacks Rank & Other Key Picks
Infinity has a Zacks Rank #2 (Buy).
A few other top-ranked stocks from the same space worth considering are Ligand Pharmaceuticals (NASDAQ:LGND) and Protagonist Therapeutics (NASDAQ:PTGX) . Both of them sport a Zacks Rank #1 (Strong Buy). You can see .
Ligand’s earnings per share estimates have moved up from $4.20 to $4.43 for 2018 over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.88%. The company’s shares have rallied 14.9% year to date.
Protagonist’s loss estimates narrowed from $1.30 to 66 cents for 2018 and from $1.99 to $1.26 for 2019, over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.95%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.